In the early 1990s, scientists working in the fields of cancer and infectious disease had been trying to develop new ways to treat cancer patients, and it was not clear if the therapies could be used for other diseases, such as HIV or AIDS.
The first breakthrough was the use of stem cells, which were able to develop into the immune cells that can fight infection and other infections.
The next breakthrough was a technique called adoptive cell transplantation, which was able to allow stem cells to turn into other types of cells and have the ability to take over the functions of the immune system.
In the 1980s, the concept of stem cell therapy was made public through a study published in Nature in 1992.
This paper, by researchers from Harvard Medical School, looked at a technique known as CRISPR-Cas9, which allowed a small number of cells to change into a specific kind of cancer cell.
The researchers found that the modified cells were able “to replicate the phenotype of cancer cells” and could be targeted to cancerous tumors.
The study, published in the journal Science in 2014, concluded that the new technology was “very promising” for treating cancers of the skin, liver, bone, and breast.
This time around, the researchers wanted to use it to treat leukemia and other cancers, but the work required a lot of specialized technology and money.
The NIH approved the project in 2010, and by the time it was done, it had more than $500 billion in funding.
The technology was initially developed by a handful of scientists in China, but they were quickly overwhelmed and their work was turned over to the NIH.
By the time the researchers were able get funding, they had developed some of the first effective stem cell therapies.
Today, they are being used by the American Cancer Society to treat some 3 million people in the U.S. and overseas.
The idea behind the project is that stem cells can be used to repair cancerous cells and help restore the immune systems of cancer patients.
The project is being run by the NIH and the National Institutes of Health.
The main goal of the project was to develop a test that could be given to patients, such that it could determine whether they had any genetic mutations that could cause their cancers to grow more quickly.
So far, the NIH has tested the test on more than 2 million people, including more than 1.5 million people diagnosed with lung cancer.
The results have been positive.
Researchers said that, at least for the first time, they could accurately tell whether a patient was carrying a mutation that would cause them to develop cancer.
They said that by testing a patient’s DNA, the test would be able to pinpoint the mutations and prevent them from developing more tumors.
This is a huge step forward for the research field.
The goal is to find out whether the genetic mutation would increase the risk of developing lung cancer, which has a 95% chance of being diagnosed in someone born in the 1980-1990s, according to the National Cancer Institute.
If the mutation is not found, the cancer will likely grow more slowly and not spread to other parts of the body.
The cost of the research is expected to be around $1 million a year for the NIH, and there are plans to raise the funding by a couple of hundred million dollars annually.
The hope is that the test could be rolled out within the next decade.
For the time being, the results have not been a surprise.
The team has been working with more than a dozen clinical trials, but none of them have shown much progress.
In a paper published in 2013, the scientists reported that they had succeeded in using stem cells in only two of the trials, which is a problem, because the cancer cells that they were able at the time were immature.
The scientists said that they would be looking to get the test approved by the FDA for approval by the end of the year.
So, the idea is to test it on patients who are already in the trials and to make sure that it works.
The FDA has not yet approved the test for human use.
The research is being supported by the National Institute of Allergy and Infectious Diseases (NIAID), and the project will be funded through grants from the National Science Foundation, National Institutes Of Health, and the Robert Wood Johnson Foundation.